BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44

Reuters11-19

BRIEF-<a href="https://laohu8.com/S/RNA">Avidity Biosciences</a> Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44

Avidity Biosciences Inc RNA.O:

AVIDITY BIOSCIENCES ANNOUNCES U.S. MANAGED ACCESS PROGRAM (MAP) FOR INVESTIGATIONAL THERAPY DEL-ZOTA IN DMD44
AVIDITY BIOSCIENCES INC - PLANS BLA SUBMISSION FOR DEL-ZOTA IN 2026

Source text: ID:nPnc78Mlha

Further company coverage: RNA.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584421439?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-19 22:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584421439","market":"nz","top_or_hot":-1,"title":"BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44</title></head><body><p>Avidity Biosciences Inc <span>RNA.O</span>:</p><ul><li><p>AVIDITY BIOSCIENCES ANNOUNCES U.S. MANAGED ACCESS PROGRAM (MAP) FOR INVESTIGATIONAL THERAPY DEL-ZOTA IN DMD44</p></li><li><p>AVIDITY BIOSCIENCES INC - PLANS BLA SUBMISSION FOR DEL-ZOTA IN 2026</p></li></ul><p>Source text: <span>ID:nPnc78Mlha</span></p><p>Further company coverage: <span>RNA.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-19 22:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/RNA\">Avidity Biosciences</a> Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44</title></head><body><p>Avidity Biosciences Inc <span>RNA.O</span>:</p><ul><li><p>AVIDITY BIOSCIENCES ANNOUNCES U.S. MANAGED ACCESS PROGRAM (MAP) FOR INVESTIGATIONAL THERAPY DEL-ZOTA IN DMD44</p></li><li><p>AVIDITY BIOSCIENCES INC - PLANS BLA SUBMISSION FOR DEL-ZOTA IN 2026</p></li></ul><p>Source text: <span>ID:nPnc78Mlha</span></p><p>Further company coverage: <span>RNA.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nTUA9GRHQQ:1","article_id":"2584421439","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584421439","pubTimestamp":1763561728,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44Avidity Biosciences Inc RNA.O:AVIDITY BIOSCIENCES ANNOUNCES U.S. MANAGED ACCESS PROGR","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","BK4505":"高瓴资本持仓","BK4139":"生物科技","RNA":"Avidity Biosciences, Inc."},"translate_title":"简介-Avidity Biosciences宣布针对Dmd44研究疗法Del-Zota的美国管理准入计划(Map)","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNA":0.9},"content_text":"BRIEF-Avidity Biosciences Announces U.S. Managed Access Program (Map) For Investigational Therapy Del-Zota In Dmd44Avidity Biosciences Inc RNA.O:AVIDITY BIOSCIENCES ANNOUNCES U.S. MANAGED ACCESS PROGRAM (MAP) FOR INVESTIGATIONAL THERAPY DEL-ZOTA IN DMD44AVIDITY BIOSCIENCES INC - PLANS BLA SUBMISSION FOR DEL-ZOTA IN 2026Source text: ID:nPnc78MlhaFurther company coverage: RNA.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584421439","isCrawlerRequest":true}